glp 1 and inflammation GLP-1 drugs calm beyond diabetes weight loss Do GLP-1 drugs reduce inflammation?

Data were extracted as follows: (1) species, number exposed to drug of interest, number of controls, timing and duration of exposure, dose (drug/kg/time-interval and equivalents to maximum recommended human dosage or clinical dosage), fetal effects of maternal GLP-1 agonist or SGLT2 inhibitor exposure, (2) species, number exposed to drug of interest, number of controls, timing and duration of exposure, dose (drug/kg/time-interval and equivalents to maximum recommended human dosage or clinical dosage), the transfer of GLP-1 agonist or SGLT2 inhibitor in maternal milk and the effect of exposure during lactation on the neonate

The mitophagy pathway and its implications in human diseases

Detection bias may be the main cause of increased cancer incidence among diabetics: results from the Rotterdam Study

And a humbling reminder that the answers to our problems may be found in unexpected places, if we are willing to look further afield, and of course, if those species and their habitats still exist by the time we get there.